NCT00806884

Brief Summary

Hypothesis: The addition of a series of musculoskeletal techniques to normal optimal care for the treatment of a respiratory exacerbation in inpatient adults with cystic fibrosis, will lead to further improvements in pain, posture, sputum clearance, lung function and quality of life.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2008

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2008

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

December 10, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 11, 2008

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2009

Completed
Last Updated

June 8, 2015

Status Verified

December 1, 2008

Enrollment Period

1.2 years

First QC Date

December 10, 2008

Last Update Submit

June 4, 2015

Conditions

Keywords

Cystic FibrosisMusculoskeletal PhysiotherapyManual therapyPosturePain

Outcome Measures

Primary Outcomes (1)

  • Thoracic index as measured by the flexicurve (Boyle, Bradley et al. 2008).

    Day 0 of admission, Days 5,10 & prior to discharge

Secondary Outcomes (6)

  • Lung function: forced expiratory volume in one second (FEV1), forced vital capacity (FVC)

    Days 0,5,10 & pre discharge

  • Pain assessment using a 10-centimetre visual analogue scale

    Days 0,5,10 & pre discharge

  • Sputum weight

    Days 0,5,10

  • Ease of sputum clearance using a 10-centimetre visual analogue scale

    Days 0,5,10 & pre discharge

  • Quality of life - CF-38 questionnaire (Ethics reference number: 98-167)

    Days 0 & pre discharge

  • +1 more secondary outcomes

Study Arms (2)

Control Arm1

OTHER

Normal optimal medical and physiotherapy treatment

Other: Control group measurements

Treatment Arm 2

EXPERIMENTAL

Physiotherapy musculoskeletal interventions in addition to normal optimal medical and physiotherapy care

Other: Physiotherapy Musculoskeletal Treatment

Interventions

Other: Physiotherapy Musculoskeletal Treatment Specific, gentle oscillatory mobilisations to the rib cage and thoracic spine of the subjects to improve joint alignment and mobility, and to reduce pain. Treatment of specific muscle dysfunction or tight muscle groups to further optimise muscle length and biomechanical relationships in the area , leading to improved efficiency of recruitment and improved power output. Postural education and awareness discussions to improve the subject's own joint alignment and ability in a functional manner. A short programme to reinforce the progress during the treatment sessions may be given.

Also known as: manual therapy, Manual techniques, physiotherapy joint mobilisations, physical therapy joint mobilisations
Treatment Arm 2

None other than control group measurements

Control Arm1

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of cystic fibrosis (genotype or sweat sodium \>70 millimoles per litre or sweat chloride of \>60 millimoles per litre)
  • years of age or over
  • Inpatient admission for respiratory exacerbation as defined by the Cystic Fibrosis Trust (Cystic Fibrosis Trust Antibiotic Group 2002)
  • Inpatients able to stand for the measurement period without cardiovascular or respiratory compromise.

You may not qualify if:

  • Current severe haemoptysis
  • Low bone density (Z score \< -3)(World Health Organisation Study Group 1994)
  • Rib fractures
  • Pregnancy
  • Inability to give consent for treatment/ measurement
  • Planned initiation or continuation of treatment in the home environment
  • Current participation in another study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Royal Brompton Hospital

London, London, SW3 6NP, United Kingdom

Location

MeSH Terms

Conditions

Cystic FibrosisPain

Interventions

Musculoskeletal Manipulations

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System DiseasesLung DiseasesRespiratory Tract DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesInfant, Newborn, DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Complementary TherapiesTherapeuticsPhysical Therapy ModalitiesRehabilitation

Study Officials

  • Professor ME Hodson

    Imperial College London

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 10, 2008

First Posted

December 11, 2008

Study Start

June 1, 2008

Primary Completion

August 1, 2009

Study Completion

August 1, 2009

Last Updated

June 8, 2015

Record last verified: 2008-12

Locations